The expression of death decoy receptor 3 was increased in the patients with primary Sjögren’s syndrome

Clinical Rheumatology

Volumn 34, Issue 5, 2015, Pages 879-885

  Liu, Jinlin ^a   Zhao, Zhao ^a   Zou, Yuqiong ^a   Zhang, Mei ^a   Zhou, Yonglie ^a   Li, Yasong ^a   Pang, Zhenzhen ^a   Jin, Weidong ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Death decoy receptor 3; ESSDAI score; Primary Sj gren s syndrome

Indexed keywords

DECOY RECEPTOR 3; HEMOGLOBIN; TNFRSF6B PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGE; AGED; BLOOD; CASE CONTROL STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; SALIVARY GLAND; SEVERITY OF ILLNESS INDEX; SJOEGREN SYNDROME; THROMBOCYTE COUNT; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PLATELET COUNT; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; SALIVARY GLANDS; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; YOUNG ADULT;

EID: 84939940553     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2853-2     Document Type: Article

References (25)

1. Zhang NZ, Shi CS, Yao QP, Pan GX, Wang LL, Wen ZX et al (1995) Prevalence of primary Sjogren’s syndrome in China. J Rheumatol 22(4):659–61
2. Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11(3):229
3. Lee CS, Hu CY, Tsai HF, Wu CS, Hsieh SL, Liu LC et al (2008) Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus. Clin Exp Immunol 151(3):383–90
4. Tai SK, Chang HC, Lan KL, Lee CT, Yang CY, Chen NJ et al (2012) Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages. J Immunol 188(5):2464–71
5. Lin WW, Hsieh SL (2011) Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol 81(7):838–47
6. Ohlsson M, Skarstein K, Bolstad AI, Johannessen AC, Jonsson R (2001) Fas-induced apoptosis is a rare event in Sjogren’s syndrome. Lab Invest 81(1):95–105
7. Bolstad AI, Eiken HG, Rosenlund B, Alarcon-Riquelme ME, Jonsson R (2003) Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjogren’s syndrome. Arthritis Rheum 48(1):174–85
8. Han B, Bojalil R, Amezcua-Guerra LM, Springall R, Valderrama-Carvajal H, Wu J et al (2008) DcR3 as a diagnostic parameter and risk factor for systemic lupus erythematosus. Int Immunol 20(8):1067–75
9. Bamias G, Siakavellas SI, Stamatelopoulos KS, Chryssochoou E, Papamichael C, Sfikakis PP (2008) Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. Clin Immunol 129(2):249–55
10. Hayashi S, Miura Y, Nishiyama T, Mitani M, Tateishi K, Sakai Y et al (2007) Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum 56(4):1067–75
11. Funke B, Autschbach F, Kim S, Lasitschka F, Strauch U, Rogler G et al (2009) Functional characterisation of decoy receptor 3 in Crohn’s disease. Gut 58(4):483–91
12. Jaffe ES. (2009) The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 523–31
13. Hernandez-Molina G, Sanchez-Hernandez T (2013) Clinimetric methods in Sjogren’s syndrome. Semin Arthritis Rheum 42(6):627–39
14. Ghadjar P, Coupland SE, Na IK, Noutsias M, Letsch A, Stroux A et al (2006) Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol 24(12):1910–6
15. Ng WF, Bowman SJ (2010) Primary Sjogren’s syndrome: too dry and too tired. Rheumatology (Oxford) 49(5):844–53
16. Ramos-Casals M, Tzioufas AG, Stone JH, Siso A, Bosch X (2010) Treatment of primary Sjogren syndrome: a systematic review. JAMA 304(4):452–60
17. Chiorini JA, Cihakova D, Ouellette CE, Caturegli P (2009) Sjogren syndrome: advances in the pathogenesis from animal models. J Autoimmun 33(3–4):190–6
18. Nocturne G, Mariette X (2013) Advances in understanding the pathogenesis of primary Sjogren’s syndrome. Nat Rev Rheumatol 9(9):544–56
19. Hayashi Y, Arakaki R, Ishimaru N (2004) Apoptosis and estrogen deficiency in primary Sjogren syndrome. Curr Opin Rheumatol 16(5):522–6
20. Nikolov NP, Illei GG (2009) Pathogenesis of Sjogren’s syndrome. Curr Opin Rheumatol 21(5):465–70
21. Bamias G, Stamatelopoulos K, Zampeli E, Protogerou A, Sigala F, Papamichael C et al (2013) Circulating levels of TNF-like cytokine 1A correlate with the progression of atheromatous lesions in patients with rheumatoid arthritis. Clin Immunol 147(2):144–50
22. Fayad R, Brand MI, Stone D, Keshavarzian A, Qiao L (2006) Apoptosis resistance in ulcerative colitis: high expression of decoy receptors by lamina propria T cells. Eur J Immunol 36(8):2215–22
23. Bamias G, Kaltsa G, Siakavellas SI, Papaxoinis K, Zampeli E, Michopoulos S et al (2010) High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis. Clin Immunol 137(2):242–9
24. Chokdeemeeboon C, Ammarinthnukrowh P, Tongkobpetch S, Srichomtong C, Deekajorndech T, Rianthavorn P et al (2013) DcR3 mutations in patients with juvenile-onset systemic lupus erythematosus lead to enhanced lymphocyte proliferation. J Rheumatol 40(8):1316–26
25. Vitali C, Palombi G, Baldini C, Benucci M, Bombardieri S, Covelli M et al (2007) Sjogren’s syndrome disease damage index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjogren’s syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum 56(7):2223–31